オーケストラ・バイオメッド・ホールディングス
Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.38 | $88,000 | -$20M |
| 2026 Q1 | -0.33 | $110,000 | -$22M |
| 2025 Q4 | 0.12 | $31M | -$2M |
| 2025 Q3 | -0.40 | $861,000 | -$15M |
| 2025 Q2 | -0.50 | $836,000 | -$16M |
| 2025 Q1 | -0.49 | $868,000 | -$17M |
| 2024 Q4 |
| -0.42 |
| $253,000 |
| -$14M |
| 2024 Q3 | -0.41 | $987,000 | -$14M |